首页> 外文期刊>British journal of ophthalmology >Photodynamic therapy with verteporfin in paediatric and young adult patients: long-term treatment results of choroidal neovascularisations.
【24h】

Photodynamic therapy with verteporfin in paediatric and young adult patients: long-term treatment results of choroidal neovascularisations.

机译:Verteporfin的光动力疗法在小儿和年轻成人患者中的应用:脉络膜新生血管的长期治疗结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Vision impairment in children and young adults may derive from choroidal neovascularisation (CNV) related to numerous conditions. The aim of this study is to highlight the applicability of photodynamic therapy using verteporfin (PDT) in these patients. METHODS: In 16 eyes of 16 consecutive patients aged 30 years or younger, prospective open-label PDT was performed. Outcomes of visual acuity as well as changes in CNV lesion parameters were evaluated. RESULTS: The mean patient age at first PDT was 19.7 (SD 8.7) years (range 6-30). 81% of the patients retained stable vision within two lines or exceedingly improved vision during follow-up of 34 (24) months. Significant vision gain was denoted in seven paediatric patients (2.7 (1.4) lines, mean (SD); p = 0.019) as well as in a subgroup of 12 patients not affected by active uveitis (2.6 (2.0) lines, p = 0.0005). Two patients with multifocal choroiditis and panuveitis (MCP) experienced vision losses of five and 11 lines after four PDT sessions despite receiving additional steroidal treatment. Except for one patient with MCP and two patients who dismissed follow-up, a mean of 2.2 (1.3) PDTs per patient sufficiently inactivated CNV lesions during follow-up. In the area of the former PDT spot, alterations of the pigment epithelium increased by 40% without correlation to changes in vision. CONCLUSIONS: The results indicate good PDT efficacy and tolerability most promising in a subgroup of patients with vision-impairing CNV not associated with active uveitis. PDT in young patients with CNV remains a valuable treatment with good risk-benefit profile over the long term.
机译:背景:儿童和年轻人的视力障碍可能源自与多种疾病相关的脉络膜新生血管形成(CNV)。这项研究的目的是强调使用维替泊芬(PDT)进行光动力疗法在这些患者中的适用性。方法:对30名或更年轻的16例连续患者的16眼进行了前瞻性开放标签PDT。评估视力结果以及CNV病变参数的变化。结果:首次PDT的平均患者年龄为19.7(SD 8.7)岁(范围6-30)。在随访的34(24)个月中,有81%的患者在两行内保持了稳定的视力或视力大大改善。在7例小儿患者(2.7(1.4)线,平均值(SD); p = 0.019)以及12例未受活动性葡萄膜炎影响的患者亚组(2.6(2.0)线,p = 0.0005)中发现了明显的视力获得。尽管接受了额外的类固醇治疗,但在两次PDT治疗后,两名患有多灶性脉络膜炎和胰腺炎(MCP)的患者视力下降了5和11行。除一名MCP患者和两名拒绝随访的患者外,每位患者平均2.2(1.3)PDT在随访期间足以使CNV病变充分失活。在前PDT点的区域,色素上皮的变化增加了40%,与视力变化无关。结论:该结果表明良好的PDT疗效和耐受性在与活动性葡萄膜炎无关的视力受损CNV患者亚组中最有希望。从长远来看,年轻CNV患者的PDT仍然是一种有价值的治疗方法,具有良好的风险收益特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号